- Norketamine
- 2-Cl-2′-Oxo-PCA
- N-Desmethylketamine
Zanos, P; Moaddel, R; Morris, PJ; Georgiou, P; Fischell, J; Elmer, GI; Gould, TD. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 1 May 2016, 533 (7604), 481–486. 6.4 MB. https://doi.org/10.1038/nature17998 #norKET LC,MS,NMR,other
Tyler, MW; Yourish, HB; Ionescu, DF; Haggarty, SJ. Classics in Chemical Neuroscience: Ketamine. ACS Chem. Neurosci., 21 Jun 2017, 8 (6), 1122–1134. 1.3 MB. https://doi.org/10.1021/acschemneuro.7b00074 #11
Harvey, M; Sleigh, J; Voss, L; Jose, J; Gamage, S; Pruijn, F; Liyanage, S; Denny, W. Development of rapidly metabolized and ultra-short-acting ketamine analogs. Anesth. Analg., 1 Oct 2015, 121 (4), 925–933. 789 kB. https://doi.org/10.1213/ANE.0000000000000719 #1
Dimitrov, I; Denny, W; Jose, J. Syntheses of ketamine and related analogues: A mini review. Synthesis, 1 Nov 2018, 50 (21), 4201–4215. 793 kB. https://doi.org/10.1055/s-0037-1609935 #Norketamine
Berger, ML; Schweifer, A; Rebernik, P; Hammerschmidt, F. NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds. Bioorg. Med. Chem., 1 May 2009, 17 (9), 3456–3462. 340 kB. https://doi.org/10.1016/j.bmc.2009.03.025 #1a NMR,IR,other